Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hit the spleen, JAK!

Steven W Lane1, Ann Mullally2

  • 1QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE;

Blood
|November 8, 2014
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Homozygous kinase-dead Csf1r mutation in outbred mice reveals essential and redundant functions of tissue resident macrophages.

Journal of leukocyte biology·2026
Same author

Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

Blood advances·2026
Same author

CD38+ monocytes fuel fibrosis in myeloproliferative neoplasm.

Blood·2026
Same author

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.

Leukemia·2026
Same author

Decoding RNA modifications to unlock new treatments for AML.

Blood·2025
Same author

Bcl-xL inhibition potentiates interferon-induced apoptosis in MPN stem cells.

Blood advances·2025
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
Same journal

Is low a go for pediatric AML?

Blood·2026
See all related articles

Researchers investigated how spleen cells from myelofibrosis (MF) patients respond to a Janus kinase (JAK) inhibitor called AZD1480. This study sheds light on potential therapeutic targets for MF.

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Biology

Background:

  • Myelofibrosis (MF) is a serious bone marrow cancer characterized by abnormal blood cell production and scarring.
  • Hematopoietic stem and progenitor cells (HSPCs) are crucial for blood formation and are implicated in MF pathogenesis.
  • Janus kinases (JAKs) play a significant role in signaling pathways involved in myeloproliferative neoplasms like MF.

Purpose of the Study:

  • To evaluate the effects of the JAK inhibitor AZD1480 on splenic-derived HSPCs from patients with myelofibrosis.
  • To understand the cellular response and potential therapeutic implications of targeting JAK signaling in MF.

Main Methods:

  • Isolation of splenic-derived hematopoietic stem and progenitor cells (HSPCs) from myelofibrosis patients.
  • Treatment of these cells with the Janus kinase (JAK) inhibitor AZD1480 in vitro.

Related Experiment Videos

  • Assessment of cellular responses, including proliferation, differentiation, and signaling pathway modulation.

    • Main Results:

    • The study reports on the specific responses observed in MF patient-derived HSPCs upon treatment with AZD1480.
    • Detailed findings regarding the modulation of JAK signaling and its downstream effects on these cells are presented.

    Conclusions:

    • The findings suggest that AZD1480 impacts the behavior of splenic HSPCs in myelofibrosis.
    • This research provides insights into the potential of JAK inhibitors as a therapeutic strategy for managing myelofibrosis.